Influence of Androgen Receptor CAG Polymorphism on Sexual Function Recovery after Testosterone Therapy in Late‐Onset Hypogonadism

2015 ◽  
Vol 12 (2) ◽  
pp. 381-388 ◽  
Author(s):  
Giacomo Tirabassi ◽  
Giovanni Corona ◽  
Andrea Biagioli ◽  
Eddi Buldreghini ◽  
Nicola delli Muti ◽  
...  
Keyword(s):  
Androgen Receptor ◽  
Sexual Function ◽  
Late Onset ◽  
Testosterone Therapy ◽  
Function Recovery ◽  
Cag Polymorphism ◽  
Late Onset Hypogonadism

scholarly journals Risks of testosterone therapy in elderly men

F1000Research ◽  
2014 ◽  
Vol 3 ◽  
pp. 11 ◽  
Author(s):  
Ranjith Ramasamy ◽  
James M. Dupree ◽  
Jason R. Kovac ◽  
Larry I. Lipshultz
Keyword(s):  
Risk Factor ◽  
Cardiovascular Risk ◽  
Bone Density ◽  
Energy Level ◽  
Independent Risk Factor ◽  
Late Onset ◽  
Elderly Men ◽  
Testosterone Therapy ◽  
Beneficial Effects ◽  
Late Onset Hypogonadism

Testosterone supplementation therapy (TST) is a widely used treatment for men with late onset hypogonadism. The benefits seen with TST, such as improved libido and energy level, beneficial effects on bone density have been well documented. Although hypogonadism remains an independent risk factor for mortality, recent studies have examined the association between testosterone therapy and cardiovascular risk.

scholarly journals Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for “late-onset” hypogonadism: A case report

2019 ◽  
Vol 7 ◽  
pp. 2050313X1882345 ◽  
Author(s):  
Ahmad Haider ◽  
Karim Haider ◽  
Farid Saad ◽  
Markolf Hanefeld
Keyword(s):  
Type 2 Diabetes ◽  
Complete Remission ◽  
Late Onset ◽  
Testosterone Deficiency ◽  
Testosterone Therapy ◽  
Urinary Tract Symptoms ◽  
Remission Of Diabetes ◽  
Clinically Significant ◽  
Late Onset Hypogonadism

For obese type 2 diabetes patients, weight reduction is one of the most important measures but fails in most cases. Testosterone deficiency can be the reason for such failure. This case presents a 57-year-old man who was referred to a urologist due to benign prostatic hyperplasia and erectile dysfunction. He had type 2 diabetes, was overweight, and had hypertension and dyslipidemia. The blood test revealed testosterone deficiency. Under testosterone therapy, the patient lost 10 kg; cardiometabolic parameters returned to normal and lower urinary tract symptoms disappeared; complete remission of diabetes was recorded. Overweight and obese patients with type 2 diabetes should be tested for hypogonadism and testosterone therapy, if indicated, be considered. These patients can considerably benefit from testosterone therapy in terms of sustainable weight loss and a clinically significant reduction of cardiometabolic risk factors including complete remission of diabetes.

scholarly journals Androgen Receptor CAG Repeat Length as a Risk Factor of Late-Onset Hypogonadism in a Korean Male Population

2018 ◽  
Vol 6 (3) ◽  
pp. 203-209 ◽  
Author(s):  
Jong Wook Kim ◽  
Young Dae Bae ◽  
Sun Tae Ahn ◽  
Jin Wook Kim ◽  
Je Jong Kim ◽  
...  
Keyword(s):  
Risk Factor ◽  
Androgen Receptor ◽  
Late Onset ◽  
Repeat Length ◽  
Cag Repeat ◽  
Male Population ◽  
Late Onset Hypogonadism
Sign in / Sign up

Export Citation Format

Share Document